Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
PRODIGY (Prolonging Dual AntiplateletTreatment after Grading Stent-inducedIntimal Hyperplasia Study)
PRODIGY (Prolonging Dual Antiplatelet Treatment afterGrading Stent-induced Intimal Hyperplasia Study)M Valgimigli (Univers...
PRODIGY: Results• Primary-end-point outcome was almost identical between the two groups• Bleeding results showed large dif...
PRODIGY: Commentary*"We now have three small studies with tantalizingly similar findings. Longer dualantiplatelet therapy ...
Become a member of http://www.theheart.org    Become a fan on Facebook: http://www.facebook.com/theheartorg          Follo...
Upcoming SlideShare
Loading in …5
×

PRODIGY trial - Summary & Results

1,099 views

Published on

http://www.theheart.org/web_slides/1303305.do

A randomized trial on Prolonging Dual Antiplatelet Treatment after Grading Stent-induced Intimal Hyperplasia (PRODIGY) to address the ongoing debate of the duration of dual antiplatelet therapy after drug-eluting-sent implantation

Published in: Health & Medicine, Technology
  • Be the first to comment

  • Be the first to like this

PRODIGY trial - Summary & Results

  1. 1. PRODIGY (Prolonging Dual AntiplateletTreatment after Grading Stent-inducedIntimal Hyperplasia Study)
  2. 2. PRODIGY (Prolonging Dual Antiplatelet Treatment afterGrading Stent-induced Intimal Hyperplasia Study)M Valgimigli (University Hospital of Ferrara, Italy)European Society of Cardiology 2011 Congress• Purpose: A randomized trial to address the ongoing debate of the duration of dual antiplatelet therapy after drug-eluting-stent implantation• Population and treatment: 2013 patients (74% with ACS and 26% with stable angina) who underwent stenting Randomized to six or 24 months of dual antiplatelet treatment: clopidogrel + aspirin• Primary outcome: All-cause mortality, nonfatal MI, or stroke at two yearsACS=acute coronary syndrome
  3. 3. PRODIGY: Results• Primary-end-point outcome was almost identical between the two groups• Bleeding results showed large differences between the two groupsPRODIGY: Efficacy resultsEnd point 6-mo dual antiplatelet therapy (%) 24-mo dual antiplatelet therapy (%) HR (95% CI)Death/MI/stroke 10.0 10.1 0.98 (0.74–1.29)Death 6.6 6.6 1.00 (0.72 –1.40)Death/MI 9.6 8.9 1.07 (0.80–1.43)PRODIGY: Bleeding results End point 6-mo dual antiplatelet therapy (%) 24-mo dual antiplatelet therapy (%) p Type 2,3 or 5 BARC* bleeding 3.5 7.4 <0.001 TIMI major bleeding 0.6 1.6 0.041 Red blood cell transfusion 1.3 2.6 0.041*BARC=Bleeding Academic Research Consortium
  4. 4. PRODIGY: Commentary*"We now have three small studies with tantalizingly similar findings. Longer dualantiplatelet therapy (up to two years) does not appear to be adding much clinicalbenefit, and there is a clear signal of increased bleeding." - Dr Magnus Ohman"Although we are still waiting for the results of larger trials, PRODIGY representsone more victory against the greatest enemy of drug-eluting stents—the wronglyassumed need for endless dual antiplatelet therapy." - Dr Adnan Kastrati*All comments from PRODIGY raises questions about longer clopidogrel duration poststenting(http://www.theheart.org/article/1272023.do)
  5. 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×